ADC Therapeutics secures USD 86.6 million PIPE for ADC Therapeutics stock

Published on 10/19/2026 at 01:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The deal is designed to extend cash runway into 2029. For ADC Therapeutics stock, 48.1 million warrants add dilution context.

Financing and cash runway

ADC Therapeutics announced a USD 86.6 million private placement on October 8, 2026.
Second-quarter 2026 revenue was USD 19.2 million and net loss was USD 16.6 million.
The PIPE is expected to close on October 22, 2026.

ADCT, CH0499880968, Illustration mit AI erstellt.

ADC Therapeutics (CH0499880968) announced a USD 86.6 million private placement on October 8, 2026, according to PR Newswire. The financing forms part of a broader restructuring intended to extend the company's expected cash runway into 2029.

Funding changes the capital structure

The PIPE includes 12.9 million common shares priced at USD 1.42 per share and pre-funded warrants for 48.1 million additional shares at USD 1.32 per warrant. ADC Therapeutics said the transaction is expected to close on October 22, 2026, subject to customary conditions.

The restructuring also removes a USD 150.0 million change-of-control payment under the HealthCare Royalty agreement. A loan amendment provides for a USD 70.0 million principal prepayment, leaving USD 50.0 million outstanding with repayment scheduled at maturity in August 2029.

What does the financing mean for dilution?

The financing provides capital for ZYNLONTA pipeline studies, including Phase 3 trials, while the warrant structure expands the potential share count. The company said net product revenue from ZYNLONTA was expected to reach USD 21.0 million for the third quarter ended September 30, 2026, and cash and cash equivalents totaled USD 189.2 million on that date.

Three dates frame the announcement

On August 13, 2026, ADC Therapeutics reported second-quarter revenue of USD 19.25 million and an adjusted loss of USD 0.11 per share, according to MarketBeat. On October 7, 2026, the company amended its royalty and loan agreements, including the USD 70.0 million prepayment. On October 8, 2026, it announced the USD 86.6 million PIPE and the related financing changes.

Next dates for investors

The PIPE is scheduled to close on October 22, 2026. The company also set October 31, 2026, as the deadline tied to the effectiveness of the HealthCare Royalty amendment, while early November brings planned LOTIS-7 and marginal zone lymphoma data abstracts.

Market context after the restructuring

ADC Therapeutics had a market capitalization of USD 179.4 million and a 52-week range of USD 0.78 to USD 4.98 as of October 16, 2026. The financing improves near-term liquidity, but the share issuance and warrants add a clear dilution factor to the capital-structure picture.